Major depressive disorder is a common condition globally, affecting a significant portion of the adult population. It’s not just a health issue but also has considerable economic implications due to its role in long-term disability and associated costs.
Traditional antidepressants and mood stabilizers have shown limited effectiveness. Only a portion of depression patients achieve remission with these treatments, and many do not respond at all. This situation is particularly challenging in bipolar disorder, where depression is a predominant issue, but few effective pharmacological treatments are available.
Intravenous ketamine, a potent NMDA antagonist, has shown promise in several controlled trials. It has demonstrated effectiveness in treating symptoms of depression in patients who have not responded to other treatments. Notably, ketamine’s effects are rapid, and it has shown a potential in reducing suicidal ideation.
Despite the encouraging results with ketamine, there’s a lack of understanding about who benefits most from this treatment. Identifying predictors of response, including potential blood-based biomarkers, could significantly enhance the effectiveness of treatment by targeting those most likely to benefit.
https://googleads.g.doubleclick.net/pagead/ads?client=ca-pub-9585941727679583&output=html&h=250&slotname=5494213682&adk=315283653&adf=765698855&pi=t.ma~as.5494213682&w=300&lmt=1706564880&format=300×250&url=https%3A%2F%2Fwww.psypost.org%2F2024%2F01%2Ftransforming-depression-treatment-ketamine-shows-promising-results-in-new-study-221125&wgl=1&uach=WyJXaW5kb3dzIiwiMTAuMC4wIiwieDg2IiwiIiwiMTIxLjAuNjE2Ny44NiIsbnVsbCwwLG51bGwsIjY0IixbWyJOb3QgQShCcmFuZCIsIjk5LjAuMC4wIl0sWyJHb29nbGUgQ2hyb21lIiwiMTIxLjAuNjE2Ny44NiJdLFsiQ2hyb21pdW0iLCIxMjEuMC42MTY3Ljg2Il1dLDBd&dt=1706631254838&bpp=1&bdt=1072&idt=391&shv=r20240124&mjsv=m202401250101&ptt=9&saldr=aa&abxe=1&prev_fmts=300×250&correlator=4696728242686&frm=20&pv=1&ga_vid=1297890863.1706631254&ga_sid=1706631255&ga_hid=39093424&ga_fc=0&u_tz=390&u_his=1&u_h=720&u_w=1280&u_ah=680&u_aw=1280&u_cd=24&u_sd=1.5&dmc=8&adx=332&ady=2012&biw=1263&bih=593&scr_x=0&scr_y=0&eid=44808398%2C42532524%2C44795921%2C95322433%2C31080697%2C95320376%2C95321626%2C95323009%2C31078663%2C31078665%2C31078670&oid=2&pvsid=2447326960592492&tmod=260015961&uas=0&nvt=1&ref=https%3A%2F%2Fnews.google.com%2F&fc=896&brdim=0%2C0%2C0%2C0%2C1280%2C0%2C1280%2C680%2C1280%2C593&vis=1&rsz=%7C%7CeEbr%7C&abl=CS&pfx=0&fu=0&bc=31&bz=1&td=1&psd=W251bGwsbnVsbCxudWxsLDNd&ifi=2&uci=a!2&btvi=2&fsb=1&dtd=397
“The main purpose of the study is to find a blood test that can help predict who will benefit from intravenous ketamine,” explained study author Sagar V. Parikh, a professor of psychiatry at the University of Michigan. “This first publication looked at whether three infusions were capable of causing remission (it was in 52% of people in less than two weeks, which is wonderful news). We believe that ketamine will be a standard and highly effective treatment for people who don’t respond to traditional antidepressants.”
Study Design and Methodology
The “Bio-K” study, an open-label, single-arm trial, was conducted from May 2017 to March 2020 and involved participants from the Mayo Clinic, the University of Michigan, Johns Hopkins University, and Pine Rest Christian Mental Health Services. To participate, individuals had to be between 18 and 65 years old and diagnosed with major depressive disorder or bipolar I or II disorder. Importantly, they needed to have a history of treatment resistance, meaning traditional antidepressants had failed them.
